Neuphoria Therapeutics Inc. NEUP
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.17M | -13.30K | 14.99M | 15.65M | 15.65M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.17M | -13.30K | 14.99M | 15.65M | 15.65M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.17M | -13.30K | 14.99M | 15.65M | 15.65M |
| SG&A Expenses | 7.44M | 7.74M | 7.47M | 7.96M | 7.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.18M | 14.65M | 16.85M | 18.56M | 16.48M |
| Operating Income | -9.01M | -14.66M | -1.86M | -2.91M | -829.10K |
| Income Before Tax | -13.59M | -17.80M | -6.08M | -9.84M | -838.00K |
| Income Tax Expenses | -139.20K | -371.00K | -417.40K | -371.00K | -468.40K |
| Earnings from Continuing Operations | -13.45 | -17.43 | -5.66 | -9.47 | -0.37 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.45M | -17.43M | -5.66M | -9.47M | -369.60K |
| EBIT | -9.01M | -14.66M | -1.86M | -2.91M | -829.10K |
| EBITDA | -8.35M | -14.00M | -1.20M | -2.25M | -166.30K |
| EPS Basic | -5.00 | -8.77 | -2.12 | -3.77 | 0.03 |
| Normalized Basic EPS | -2.58 | -5.49 | -1.37 | -2.55 | -0.24 |
| EPS Diluted | -6.19 | -9.95 | -3.31 | -4.32 | -0.53 |
| Normalized Diluted EPS | -2.58 | -5.49 | -1.37 | -2.55 | -0.24 |
| Average Basic Shares Outstanding | 17.60M | 14.09M | 10.40M | 7.44M | 6.50M |
| Average Diluted Shares Outstanding | 17.60M | 14.09M | 10.40M | 7.44M | 6.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |